Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
Type:
Grant
Filed:
August 12, 2016
Date of Patent:
October 1, 2019
Assignees:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHNGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
George Pavlakis, Barbara Felber, James Mullins
Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
Type:
Grant
Filed:
April 17, 2017
Date of Patent:
October 1, 2019
Assignees:
Beth Israel Deaconess Medical Center, Inc., TRIAD NATIONAL SECURITY, LLC
Inventors:
Dan H. Barouch, Bette T. Korber, William M. Fischer
Abstract: Provided herein is a method of detecting the presence of influenza virus in a sample while minimizing false positives due to presence of one or more other pathogens in the sample, the method including measuring the enzymatic activity of neuraminidase (NA) in the sample under one or more differentiating conditions selected from the group consisting of pH, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition, and combinations thereof.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
September 10, 2019
Assignees:
University of Cincinnati, MicrobeCapture, LLC
Inventors:
Alison A. Weiss, Karen Melissa Gallegos Villalobos, David Ralph
Abstract: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
August 6, 2019
Assignee:
VIROCURE, INC.
Inventors:
Manbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
Abstract: The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
July 23, 2019
Assignee:
Laboratory Corporation of America Holdings
Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
Type:
Grant
Filed:
October 7, 2016
Date of Patent:
June 25, 2019
Assignee:
OLOGY BIOSERVICES INC.
Inventors:
Falko-Günter Falkner, Birgit Schafer, P Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
Type:
Grant
Filed:
June 22, 2015
Date of Patent:
June 11, 2019
Assignees:
INSTITUT PASTEUR, INSTITUT PASTEUR DU CAMBODGE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Frederic Tangy, Anavaj Shakuntabai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
June 11, 2019
Assignee:
The Penn State Research Foundation
Inventors:
Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
Abstract: The instant disclosure provides norovirus binding aptamers, compositions comprising such aptamers, and methods of using and producing such aptamers. The aptamers are useful, for example, for detecting the presence of norovirus in test samples, for capturing and/or concentrating norovirus from test samples, for evaluating the efficacy of therapeutic agents in patients diagnosed with a norovirus infection, and for evaluating the efficacy of norovirus vaccines.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
June 4, 2019
Assignee:
NORTH CAROLINA STATE UNIVERSITY
Inventors:
Lee-Ann Jaykus, Blanca Irene Escudero-Abarca, Matthew D. Moore, Helen Rawsthorne
Abstract: The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
June 4, 2019
Assignee:
Yale University
Inventors:
Margarita Dominguez-Villar, David A. Hafler
Abstract: Novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
May 28, 2019
Assignee:
Biological Mimetics, Inc.
Inventors:
Peter L Nara, Gregory J Tobin, George Lin
Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.
Type:
Grant
Filed:
November 4, 2014
Date of Patent:
May 28, 2019
Assignee:
Phio Pharmaceuticals Corp.
Inventors:
William R. Levis, Leonard L. Kaplan, John G. Callahan
Abstract: The invention relates to non-integrative lentiviral vectors and their use for the stable transgenesis of both dividing and no-dividing eukaryotic cells. The invention also provides methods for obtaining these vectors, the use of these vectors for the production of recombinant lentiviruses, and the use of these recombinant lentiviruses for obtaining a cell able to stably produce a product of interest.
Type:
Grant
Filed:
November 27, 2014
Date of Patent:
May 21, 2019
Assignee:
FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARIOVASCULARES CARLOS III (CNIC)
Inventors:
Juan Carlos Ramírez Martínez, Raúl Torres Ruiz, Aida García Torralba
Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
Type:
Grant
Filed:
February 27, 2017
Date of Patent:
May 21, 2019
Assignee:
University of Florida Research Foundation, Incorporated
Inventors:
Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
Type:
Grant
Filed:
March 31, 2017
Date of Patent:
May 21, 2019
Assignees:
ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE, KYOWA HAKKO KIRIN CO., LTD
Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
Abstract: A new non-HIV vaccine antigen from Mycoplasma sp. permease capable of inducing a mucosal neutralizing protective antibody response against HIV infection, a neutralizing antibody directed to said antigen, and a method for the identification of new antigens from the mucosal microbiota for the development of vaccines against pathogens.
Type:
Grant
Filed:
February 5, 2015
Date of Patent:
April 30, 2019
Assignee:
B Cell Design SAS
Inventors:
Raphaëlle Claude El Habib, Régis Sodoyer, Armelle Cuvillier, Christiane Moog